A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12

Population: The Efficacy dataset included all participants who received at least 1 infusion of LCIG study drug and had a baseline and LCIG Treatment Period observation for at least one efficacy or health outcome measure.

The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The Total UPDRS score includes 31 items contributing to three subscales: (I) Mentation, Behavior, and Mood; (II) Activities of Daily Living; and (III) Motor Examination. Each question is answered on a scale from 0 (None) to 4 (Severe); Some questions require multiple grades assigned to each extremity. The UPDRS Total score was computed as the sum of these 3 UPDRS subscales and ranged from 0 to 176, with 176 representing the worst (total) disability, and 0 no disability.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at baseline (37) and each time point

CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The between errors score is the number of times the participant revisited a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance.

Time frame: Baseline and Week 12

Population: Efficacy dataset with available data

CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance.

Time frame: Baseline and Week 12

Population: Efficacy dataset with available data

Letter fluency was assessed using a paper and pen test, in which participants were asked to generate as many words as possible in 60 seconds, starting with the letters F, A, or S. The COWAT All Letters score is the number of words recalled in all post-baseline assessments, regardless of letter used. The COWAT Baseline Letter score is the number of words recalled in post-baseline assessments that used the same letter as at Baseline.

Time frame: Baseline and Week 60

Population: Efficacy dataset with available data

The Health-Related Productivity Questionnaire (HRPQ) is a generic measure of the impact of disease on the ability of the participant to be productive at paid employment or at performance of household chores. Questions inquire about the amount of time they were scheduled/planned to work, the number of the scheduled/planned hours they were able to work and their ability to be productive for the hours of work they did perform. Absenteeism: Number of hours not worked due to PD or it's treatments; Presenteeism: Number of hours of lost productivity while at work due to PD or it's treatments; Total hours lost: Number of hours lost due to absenteeism and presenteeism

Time frame: Baseline, Week 12 and Week 60

Population: Efficacy dataset with available data. Workplace hours lost is calculated for participants who were employed.

The Parkinson's Disease Diary was completed by the participant for 3 consecutive days prior to each visit for the full 24 hours of each day. Participants recorded whether they had been On, Off, or Asleep and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from time asleep. Off time was defined as time when medication has worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. Parkinson's Disease Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PD Diary was completed by the participant for 3 consecutive days prior to each visit. Participants recorded whether they had been On, Off, or Asleep and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from sleep. On was defined as time when medication was providing benefit with regard to mobility, slowness, and stiffness. On time without troublesome dyskinesia is a composite of On time without dyskinesia (involuntary twisting, turning movements which are an effect of medication) plus On time with non-troublesome dyskinesia (dyskinesia that does not interfere with function or cause meaningful discomfort). PD Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS cardiovascular including falls domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time points

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). The PDQ-39 Summary Index (PDQ-SI) is the sum of all answers divided by the highest score possible (i.e., number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0 - 100 scale where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The dyskinesia items score includes questions 32, 33 and 34 from the complications of therapy section of the UPDRS which address dyskinesia duration, disability, and pain. Each question was answered on a scale from 0 (Normal) to 4 (Severe); the UPDRS dyskinesia items score was computed as the sum of these items and ranged from 0 (not affected) to 12 (most severely affected).

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The activities of daily living score includes 13 items addressing speech, salivation, swallowing, handwriting, cutting food, dressing, hygiene, turning in bed, falling, freezing, walking, tremor, and sensory complaints. Each question is answered on a scale from 0 (Normal) to 4 (Severe). The UPDRS Part II: activities of daily living score was computed as the sum of these items and ranged from 0 (not affected) to 52 (most severely affected).

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at baseline (37) and at each time point

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The motor examination score includes 17 items addressing speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. Each question is answered on a scale from 0 (Normal) to 4 (Severe), some items include multiple grades for each extremity. The UPDRS Part III: motor examination score was computed as the sum of these items and ranged from 0 (not affected) to 108 (most severely affected).

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at baseline (37) and at each time point

The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The mentation, behavior, and mood score includes 4 items addressing intellectual impairment, thought disorder, motivation/initiative, and depression. Each question is answered on a scale from 0 (None) to 4 (Severe). The UPDRS Part I: mentation, behavior, and mood score was computed as the sum of these items and ranged from 0 (not affected) to 16 (most severely affected).

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at baseline (37) and each time point

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The complications of therapy section includes 11 items addressing dyskinesia duration, disability, and pain, early morning dystonia, offs-predictable, offs-unpredictable, offs-sudden, offs-duration, anorexia-nausea-vomiting, sleep disturbance, and symptomatic orthostasis. Four questions are answered on a scale from 0 (Normal) to 4 (Severe) and seven on a binary scale where 0=No and 1=Yes. The UPDRS Part IV: complications of therapy score was computed as the sum of these items and ranged from 0 (not affected) to 23 (most severely affected).

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The modified Hoehn and Yahr scale is as follows: * Stage 0: No signs of disease * Stage 1.0: Symptoms are very mild; unilateral involvement only * Stage 1.5: Unilateral and axial involvement * Stage 2: Bilateral involvement without impairment of balance * Stage 2.5: Mild bilateral disease with recovery on pull test * Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent * Stage 4: Severe disability; still able to walk or stand unassisted * Stage 5: Wheelchair bound or bedridden unless aided

Time frame: Baseline and Week 12 and Week 60

Population: Efficacy dataset with available data at each time point

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame: Baseline and Week 60

Population: Efficacy dataset with available data at baseline and week 60

Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The Week 4 version of the questionnaire addressed the following questions during the first four weeks after the PEG-J procedure: 1. Has the subject had a visit to an emergency room? 2. Has the subject had a visit to an urgent care? 3. Has the subject had an outpatient visit to a neurologist? 4. Has the subject had an outpatient visit to a gastroenterologist, surgeon, or interventional radiologist? 5. Has the subject had an outpatient visit to a primary care physician? 6. Has the subject called the nursing support line? 7. Has the subject called a physician?

Time frame: Weeks 1-4

Population: The Safety dataset included all participants who underwent the PEG-J placement procedure

Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The standard version of the questionnaire addressed the following questions over the last 3 months: 1. Has the subject had a visit to an emergency room? 2. Has the subject had an outpatient visit to any of the following healthcare providers? 3. Has the subject been visited in his or her place of residence by a health care professional? 4. Has the subject received assistance from either of the following for their Parkinson's disease in their home? 5. Has the subject needed to contact either of the following for immediate assistance related to their Parkinson's disease? 6. Have family members or friends had to miss any paid work due to the subject's Parkinson's disease? 7. Has the subject fallen during the past month?

Time frame: Week 60

Population: Safety dataset with available data

Adverse events (AEs) related to treatment are those the investigator determined as having a reasonable possibility being related to study drug based on evidence to suggest a causal relationship between the study drug and the adverse event. A severe AE was defined as an adverse event that caused considerable interference with the participant's usual activities and might be incapacitating or life-threatening. Serious AEs were defined as those that were life-threatening or resulted in death, hospitalization or prolongation of hospitalization, a congenital anomaly, persistent or significant disability/incapacity, or important medical events requiring medical or surgical intervention to prevent a serious outcome.

Time frame: Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days)

Population: The Safety dataset

The PGIC is a 7-point response scale. Participants were asked to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of Very much improved, Much improved and Minimally improved on the PGIC were used to define responders.

Time frame: Week 12 and Week 60

Population: Efficacy dataset

The Treatment Satisfaction Questionnaire (TSQ) is a single item instrument developed by the Sponsor on which the participant indicated their level of satisfaction or dissatisfaction with their PD treatment. The responses are recorded on a Likert-type scale (Very Satisfied, Satisfied, Somewhat Satisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied).

Time frame: Week 12 and Week 60

Population: Efficacy dataset